Crohn's Disease and Ulcerative Colitis : From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach
https://libcat.nshealth.ca/en/permalink/provcat41327
Daniel C. Baumgart, editor.
(Second edition)
--Cham:
Springer
, 2017.
- Available Online
- View e-Book
- Location
- Online
This new edition is a unique combined resource for physicians and scientists addressing the needs of both groups. In addition to stimulating exchange and collaboration and shortening the path between discovery and application of new knowledge, the book helps clinicians understand new therapeutic concepts from their origins. The volume serves as a comprehensive guide to the current diagnostic modalities, including enhanced imaging techniques such as MRI and CT enterography, virtual colonoscopy, …
- Available Online
- View e-Book
- Other Authors
- Baumgart, Daniel C
- Responsibility
- Daniel C. Baumgart, editor
- Edition
- Second edition
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- 2017
- Physical Description
- 1 online resource (xx, 695 pages) : 204 illus., 144 illus. in color
- ISBN
- 9783319337036
- 9783319337012 (print ed.)
- Subjects (MeSH)
- Colitis, Ulcerative
- Crohn Disease
- Abstract
- This new edition is a unique combined resource for physicians and scientists addressing the needs of both groups. In addition to stimulating exchange and collaboration and shortening the path between discovery and application of new knowledge, the book helps clinicians understand new therapeutic concepts from their origins. The volume serves as a comprehensive guide to the current diagnostic modalities, including enhanced imaging techniques such as MRI and CT enterography, virtual colonoscopy, ultrasound, and endomicroscopy, as well as conventional and complex immunomodulatory principles. The latest edition also includes revised chapters from the previous edition, as well as new chapters reflecting current developments in the field. Written by experts in their field, Crohn's Disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach, Second Edition is of great value to gastroenterologists, surgeons, internists, pediatricians and gynecologists trainees, as well as all those involved in Crohn's disease, ulcerative colitis, and related autoimmune disorders.
- Contents
- Part I. Epidemiology -- Environmental Factors in the Epidemiology of Inflammatory Bowel Disease -- Part II. Immunobiology -- The Immune System in Health -- Understanding the Epithelial Barrier in IBD -- Intestinal Microbiology and Ecology in Crohn's Disease and Ulcerative Colitis -- The Immune System in Inflammatory Bowel Disease: Antimicrobial Peptides -- Vascular Responses to Intestinal Inflammation -- Immunobiology of Human Dendritic Cells in Inflammatory Bowel Disease -- Immunobiology of T-cells in Inflammatory Bowel Disease -- Immunology of B-cells in Inflammatory Bowel Disease -- Immune Cells: Monocytes and Macrophages -- Immune Functions of Epithelial Cells in Inflammatory Bowel Disease -- Autophagy and Endoplasmic Reticulum Stress -- Matrix Metalloproteinases -- Paradigm of T-cell Differentiation in Irritable Bowel Disease -- Pharmacological Intervention Studies Using Mouse Models of Chronic Intestinal Inflammation -- Stem Cells and Organoids to Study Epithelial Cell Biology in Inflammatory Bowel Disease -- Part III. Diagnostic Approach -- Enhanced Endoscopy -- Magnetic Resonance Enterography -- Computed Tomography Enterography and Inflammatory Bowel Disease -- Ultrasound in Inflammatory Bowel Disease -- Laboratory Evaluation, Including Novel Diagnostic Markers -- Pathology of Inflammatory Bowel Disease -- Objective Assessment of Clinical Disease Activity -- Objective Assessment of Endoscopic Disease Activity and Mucosal Healing -- Evaluation of Quality of Life in Crohn's Disease and Ulcerative Colitis: What Is Health-Related Quality of Life? -- Evaluation of Health Economics in Inflammatory Bowel Disease -- Part IV. Therapy: Crohn’s Disease -- The Natural History of Inflammatory Bowel Disease -- Conventional Medical Management of Crohn's Disease: Sulfasalazine -- Steroid Therapy for Crohn's Disease -- Thiopurines in Crohn's Disease -- Conventional Medical Management of Crohn's Disease: Methotrexate -- Adalimumab for the Treatment of Crohn's Disease -- Biologic Therapy of Crohn's Disease: Certolizumab -- Biologic Therapy of Crohn's Disease: Infliximab -- Briakinumab and Ustekinumab: Anti-p40 Antibodies for Inflammatory Bowel Disease Treatment -- Biologic Therapy of Crohn's Disease: Natalizumab, Vedolizumab and anti-MadCAM -- Optimal Management of Fistulizing Crohn's Disease -- Part V. Therapy: Ulcerative Colitis -- Sulfasalazine and 5-aminosalicylates for Ulcerative Colitis -- Conventional Therapy of Ulcerative Colitis: Corticosteroids -- Medical Management of Ulcerative Colitis: Conventional Therapy: Azathioprine -- Calcineurin Inhibitors in Ulcerative Colitis -- Biologic Therapy in Moderate-to-Severe Ulcerative Colitis: Infliximab -- Biologic Therapy of Ulcerative Colitis: Adalimumab -- Biologic Therapy of Ulcerative Colitis: Golimumab -- Biologic Therapy of Ulcerative Colitis: Natalizumab, Vedolizumab, Etrolizumab (rHUMab beta 7), antiMadCAM -- Probiotics, Prebiotics, and Antibiotics in Inflammatory Bowel Disease -- Biosimilars in the Treatment of Inflammatory Bowel Disease -- Step-up versus Top-down Approach in Crohn's Disease -- Leukocytapheresis Therapy of Inflammatory Bowel Diease -- Surgical Management of Crohn's Disease and Ulcerative Colitis -- Part VI. Extraintestinal Manifestations -- Extraintestinal Manifestations: Autoimmune Hepatitis -- Primary Sclerosing Cholangitis -- Autoimmune Pancreatitis and Other Organ Involvement -- Cutaneous and Oral Manifestations of Inflammatory Bowel Disease -- Arthritis, Arthropathy and Osteoporosis in Inflammatory Bowel Disease -- Part VII. Nutrition -- Nutrition in Inflammatory Bowel Disease -- Part VIII. Pregnancy, Family Planning and Pediatric Aspects -- Pregnancy and Fertility in Inflammatory Bowel Disease -- Pediatric Aspects of Inflammatory Bowel Disease -- Part IX. Surveillance and Prevention -- Management and Prevention of Infectious Diseases in Inflammatory Bowel Disease Patients -- Incidence of Cancer and Screening in Inflammatory Bowel Disease -- Inflammatory Bowel Diseases: How to Identify High Risk Patients -- Part X. Patient Perspective and Resources -- Patient Perspective on Inflammatory Bowel Disease -- Patient Resources in Inflammatory Bowel Disease.
- Format
- e-Book
- Location
- Online
Crohn's Disease and Ulcerative Colitis : From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach
https://libcat.nshealth.ca/en/permalink/provcat30928
Daniel C. Baumgart, editor.
--New York, NY:
Springer
, c2012.
- Available Online
- View e-Book
- Location
- Online
The conditions of Crohn's disease and ulcerative colitis are excellent examples of how the exponential growth of knowledge in biomedical science can make a remarkable impact on clinical practice and patient's quality of life. It has led to the development of unique novel immunomodulatory treatments. These are continuously being refined to treat not only the two original conditions in the gut, but the systemic immunologic illness with its associated extraintestinal disorders. New therapies are …
- Available Online
- View e-Book
- Other Authors
- Baumgart, Daniel C
- Responsibility
- Daniel C. Baumgart, editor
- Place of Publication
- New York, NY
- Publisher
- Springer
- Date of Publication
- c2012
- Physical Description
- 1 online resource (xviii, 754 p. : 151 ill., 116 ill. in color)
- ISBN
- 9781461409984
- Subjects (MeSH)
- Colitis, Ulcerative
- Crohn Disease
- Subjects (LCSH)
- Gastroenterology
- Abstract
- The conditions of Crohn's disease and ulcerative colitis are excellent examples of how the exponential growth of knowledge in biomedical science can make a remarkable impact on clinical practice and patient's quality of life. It has led to the development of unique novel immunomodulatory treatments. These are continuously being refined to treat not only the two original conditions in the gut, but the systemic immunologic illness with its associated extraintestinal disorders. New therapies are sometimes complex and associated with important risks requiring a deeper understanding of their molecular principles from clinicians. Crohn's Disease and Ulcerative Colitis serves as a unique combined resource for physicians and scientists addressing the needs of both groups. It will stimulate exchange and collaboration and shorten the path between discovery and application of new knowledge and also help clinicians understand new therapeutic concepts from their origins. This volume provides an introduction to mucosal immunology which forms the basis of modern immunotherapy. It also serves as a comprehensive guide to the current diagnostic modalities, including enhanced imaging techniques such as MRI and CT enterography, virtual colonoscopy, ultrasound, and endomicroscopy as well as conventional and complex immunomodulatory principles. Each chapter is written by experts in their field and includes the most up to date information. Crohn's Disease and Ulcerative Colitis will be of great value to gastroenterologists, surgeons, internists, pediatricians and gynecologists trainees, as well as all those involved in Crohn's disease, ulcerative colitis and related autoimmune disorders.
- Contents
- The genetics of inflammatory bowel disease -- Environmental factors in the epidemiology of inflammatory bowel disease -- The intestinal immune system in health -- Understanding the epithelial barrier in inflammatory bowel disease -- Intestinal microbiology and ecology in inflammatory bowel disease -- Microbial recognition and pathogen-associated molecular pattern (PAMP) receptors in inflammatory bowel disease -- Inflammasomes in inflammatory bowel disease -- Antimicrobial peptides in inflammatory bowel disease -- Vascular responses to intestinal inflammation in inflammatory bowel disease -- Immunobiology of dendritic cells in inflammatory bowel disease -- Immunobiology of T-Cells in inflammatory bowel disease -- Immunobiology of B-Cells in inflammatory bowel disease -- Immunobiology of monocytes and macrophages in inflammatory bowel disease -- Immunobiology of epithelial cells in inflammatory bowel disease -- The Th1, Th2 and Th17 paradigm in inflammatory bowel disease -- Preclinical studies using mouse models of inflammatory bowel disease -- Enhanced endoscopy in inflammatory bowel disease -- MRI in Inflammatory Bowel Disease -- CT in inflammatory bowel disease -- Ultrasound in inflammatory bowel disease -- Laboratory evaluation including novel diagnostic markers of inflammatory bowel disease -- Histology and pathology of inflammatory bowel disease -- Activity indices based assessment of disease activity in inflammatory bowel disease -- Endoscopic assessment of disease activity and mucosal healing in inflammatory bowel disease -- Evaluation of quality of life in inflammatory bowel disease -- The natural history of inflammatory bowel disease -- Conventional medical management of Crohn's disease: sulfasalazine -- Conventional medical management of Crohn's disease: corticosteroids -- Conventional medical management of Crohn's disease: azathioprine and 6-mercaptopurine -- Conventional medical management of Crohn's Disease: Methotrexate -- Biologic Treatment of Crohn's Disease: Adalimumab -- Biologic Treatment of Crohn's Disease: Certolizumab -- Biologic Therapy of Crohn's disease: Infliximab -- Biologic Treatment of Crohn's Disease: briakinumab and ustekinumab -- Biologic Treatment of Crohn's Disease: natalizumab, vedolizumab and edrolizumab (rHUMab beta 7) -- Conventional medical management of ulcerative colitis: sulfasalazine and 5-aminosalicylates -- Conventional medical management of ulcerative colitis: corticosteroids -- Conventional medical management of ulcerative colitis: azathioprinetherapy: Azathioprine -- Conventional medical management of ulcerative colitis: cyclosporine -- Conventional medical management of ulcerative colitis: tacrolimus -- Biologic therapy of ulcerative colitis: infliximab and adalimumab -- Biologic therapy of ulcerative colitis: natalizumab, vedolizumab, edrolizumab (rHUMab beta 7) -- Probiotics, prebiotics, and antibiotics in medical management inflammatory bowel disease -- Step-Up vs. Top-Down Approach in medical management of inflammatory bowel disease -- Surgical management of Crohn's disease and ulcerative colitis -- Extraintestinal manifestations of inflammatory bowel disease: autoimmune hepatitis -- Extraintestinal manifestations of inflammatory bowel disease: primary sclerosing cholangitis (PSC) -- Extraintestinal manifestations of inflammatory bowel disease: autoimmune pancreatitis and other IgG4-related conditions -- Extraintestinal manifestations of inflammatory bowel disease: cutaneous and oral manifestations of inflammatory bowel disease -- Extraintestinal manifestations of inflammatory bowel disease: arthritis, arthropathy and osteoporosis -- Nutrition in inflammatory bowel disease -- Fertility and pregnancy in inflammatory bowel disease -- Pediatric aspects in inflammatory bowel disease -- Management and prevention of infectious diseases in inflammatory bowel disease patients -- Diagnosis and management of colorectal neoplasia in patients with inflammatory bowel disease -- How to identify high risk patients in inflammatory bowel disease? -- Patient perspective on inflammatory bowel disease -- Patient resources in inflammatory bowel disease.
- Format
- e-Book
- Location
- Online
Fibrostenotic Inflammatory Bowel Disease
https://libcat.nshealth.ca/en/permalink/provcat42704
edited by Florian Rieder.
--Cham:
Springer
, c2018.
- Available Online
- View e-Book
- Location
- Online
This book provides a comprehensive account of the pathogenesis and treatment of intestinal fibrosis, covering both the clinical and molecular aspects of the disease. It begins by describing the epidemiology and genetics of fibrostenosing IBD in Crohn's disease and Ulcerative colitis as well as the epigenetics and cellular and molecular mechanisms of the disease. Readers will obtain an in-depth overview of the disease from biomarkers and histology to surgical intervention, imaging and current an…
- Available Online
- View e-Book
- Other Authors
- Rieder, Florian
- Responsibility
- edited by Florian Rieder
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- c2018
- Physical Description
- 1 online resource (xii, 397 p.) : 70 illus., 67 illus. in color
- ISBN
- 9783319905785
- 9783319905778 (print ed.)
- 9783319905792 (print ed.)
- Subjects (MeSH)
- Fibrosis
- Crohn Disease
- Colitis, Ulcerative
- Specialty
- Gastroenterology
- Abstract
- This book provides a comprehensive account of the pathogenesis and treatment of intestinal fibrosis, covering both the clinical and molecular aspects of the disease. It begins by describing the epidemiology and genetics of fibrostenosing IBD in Crohn's disease and Ulcerative colitis as well as the epigenetics and cellular and molecular mechanisms of the disease. Readers will obtain an in-depth overview of the disease from biomarkers and histology to surgical intervention, imaging and current and future drug therapies. Medical management of fibrosis, endoscopy and imaging as well as surgical approaches are all discussed. Through the links to videos contained in the book, the reader will become familiar with interventional procedures such as endoscopic balloon dilation and surgical techniques for stricturing IBD, such as resection and strictureplasties. This is an indispensable volume for anyone working on fibrostenotic IBD, such as gastroenterologists, internists, radiologists, colorectal surgeons, pathologists and researchers. It has been written by a team of top experts from North America, Asia and Europe.
- Contents
- Fibrostenotic Inflammatory Bowel Disease—a Cinderella story -- Epidemiology and Natural History of Fibrostenosing Inflammatory Bowel Disease -- Genetic influences on the development of fibrosis in inflammatory bowel disease -- Epigenetic regulation of intestinal fibrosis -- Cytokine and Anti-cytokine Agents as Future Therapeutics for Fibrostenosing IBD -- Inflammation-independent mechanisms of intestinal fibrosis: the role of the extracellular matrix -- Fat and Fibrosis -- Environmental factors and their influence on intestinal fibrosis -- Animal models and sources of mesenchymal cells in intestinal fibrosis -- Fibrosis in Ulcerative Colitis -- Histopathology of intestinal fibrosis -- Clinical, Cellular and Serologic Biomarkers of intestinal fibrosis -- The future of intestinal fibrosis imaging -- Imaging in intestinal fibrosis. What is state of the art? -- Medical therapy of stricturing IBD -- Endoscopic therapy of intestinal strictures Çô What is state of the art? -- Resectional surgery for intestinal strictures Çô What is state of the art? -- Management of ileal pouch strictures and anal stricturing disease—A clinical challenge -- The future of surgical therapy of stricturing IBD -- Challenges of translation of anti-fibrotic therapies into clinical practice in IBD -- What distinguishes mechanisms of fistula and stricture formation -- The Pathogenesis of Intraabdominal Adhesions:Similarities and Differences to Luminal Fibrosis -- Anti-fibrotic therapies from other organs—What the gut can learn from the liver, skin, lung and heart.
- Format
- e-Book
- Location
- Online
Vedolizumab (Entyvio) therapy
https://libcat.nshealth.ca/en/permalink/chpams35620
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program.
Halifax, NS:
Nova Scotia Health Authority
, 2022.
- Pamphlet Number
- 1623
- Available Online
- View Pamphlet
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when und…
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2022
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (11 p.) : digital, PDF file
- Subjects (MeSH)
- Gastrointestinal Agents
- Colitis, Ulcerative - drug therapy
- Crohn Disease - drug therapy
- Subjects (LCSH)
- Gastrointestinal agents
- Ulcerative colitis
- Crohn's disease
- Specialty
- Medications
- Abstract
- Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when undergoing this treatment are provided.
- Responsibility
- Prepared by: Nova Scotia Collaborative IBD Program
- Pamphlet Number
- 1623
